

# Curriculum Vitae

## Dieter Weinand

### Personal data

Year of birth: 1962  
Nationality: US-American  
Independence: yes

### Member of the Supervisory Board of Evotec

Designated first appointment: 2026  
Designated term of office: 2026 – 2028

### Competences and experiences

Dieter Weinand brings more than 30 years of leadership experience in the global pharmaceutical and biopharmaceutical industry. He has held senior executive and general management positions at leading multinational companies including Bristol Myers Squibb, Sanofi, Bayer and Pfizer with full P&L responsibility and broad international exposure.

Over the past five years, he has focused on Non-Executive Director roles, primarily supporting innovation-driven biotechnology companies. He has extensive experience in governance and chairmanship responsibilities across public and private organizations and is well regarded for his ability to act as an integrative Chair, providing strategic oversight while constructively supporting executive leadership teams, particularly during periods of transformation or operational challenge.

His sector expertise spans multiple therapeutic areas, including cardiology, oncology, pulmonology, dermatology, immunology, and inflammation. He combines deep scientific and commercial understanding with a strong belief in the strategic value of innovation as a primary driver of long-term company success.

Mr. Weinand has a proven track record in driving change management initiatives, business optimization, and performance improvement on a global scale. He has led major product launches and commercial transformations, strengthening accountability, execution discipline, and portfolio focus across diverse geographies and product lines.

He is known for his high-energy, results-oriented approach and his ability to contribute effectively at board level through strategic insight, independence of thought, and a strong international network of industry stakeholders and investors. Having lived and worked extensively in the United States, Latin America, Asia and Europe, he brings a truly global perspective. He has family ties to Germany, speaks basic German, and has a solid understanding of German business culture.

Mr. Weinand holds a B.A. in Biology from Concordia College, New York, and an M.S. in Pharmacology and Toxicology from Long Island University, New York.

### **Current occupation**

Professional Non-Executive Board Member of Board of directors in various companies.

### **Career highlights**

<b>2018 – 2020</b>	<b>Sanofi</b> Executive Vice President, Primary Care
<b>2014 – 2018</b>	<b>Bayer</b> President and Chief Executive Officer, Bayer Pharma
<b>2013 – 2014</b>	<b>Otsuka</b> President, Global Commercialization
<b>2010 – 2013</b>	<b>Pfizer</b>
2012 – 2013	President, Primary Care, Asia Pacific and Canada
2010 – 2012	President, Asia Pacific
<b>2001 – 2010</b>	<b>Bristol Myers Squibb</b>
2009 – 2010	President, Intercontinental
2005 – 2009	President, Latin America, Caribbean and Canada
2004 – 2005	Senior Vice President, Brand Commercialization, Global Marketing
2002 – 2004	Vice President, Neuroscience, Global Brand Champion, Abilify
2001 – 2002	Vice President, Global Marketing, Immunology, Inflammation, Pulmonology and Dermatology

### **Qualifications**

1985 – 1987	Long Island University, Brooklyn, New York M.S. Pharmacology / Toxicology
1983 – 1984	New York Medical College, Valhalla, New York
1979 – 1982	Concordia College, Bronxville, New York B.A. Biology / Pre-Medicine

### **Current Board Affiliations**

2018 – present	Replimune Group, Inc. (Public)
2023 – present	Confo Therapeutics NV (Private) (Chair)
2021 – present	Fore Biotherapeutics Inc. (Private) (Chair)
2024 – present	Disco Pharmaceuticals GmbH (Advisory Board) (Private)
2024 – present	Clasp Therapeutics, Inc. (Private) (Chair)
2025 – present	Sibylla Biotech S.p.A. (Private) (Chair)

**Current Boards that will be exited throughout the year 2026:**

2023 – present	Coya Therapeutics, Inc. (Public)
2025 – present	AstriVax Therapeutics NV (Private) (Chair)

**Former Board Affiliations**

2024 – 2026	Anaveon AG (Private) (Chair) (resigned in March 2023)
2025 – 2026 (May)	Orogen Therapeutics, Inc. (Private) (resignation is scheduled as of May 31)
2024 – 2025	Meliora Therapeutics (Private) (Chair)
2021 – 2026	Inspirna Inc. (Private) (Chair)
2021 – 2024	Mnemo Therapeutics SAS (Private) (Chair)
2020 – 2023	Reunion Neuroscience Inc. (Private)
2015 – 2019	HealthPrize Technologies LLC (Private)
2022 – 2024	Umoja Biopharma, Inc. (Private) (Chair)
2020 – 2022	Field Trip Health Inc. (Public)
2020 – 2024	Ziel Bio Inc. (Private)

*Last update April 2026*